SVP & CCO Patton Cynthia M sold 1,777 shares in Amgen Inc. (NASDAQ:AMGN) for $21,571 in transaction occurred on 2018/11/29. After making this transaction, the SVP & CCO owns a direct stake of 360,518 shares, worth $4,265,881, as per the last closing price. On 2018/07/16 Harper Sean E, EVP, Research & Development at AMGN, dumped 1,525 shares at an average price of $195.71 per share. The selling total is valued at $11,090,776.
Separately, it had been reported that some other AMGN insiders also took part of the insider trading activity. EVP, Research & Development, Harper Sean E had divested 1,525 shares for $57,510 through a trade on 2018/06/12. Following this activity, the insider holds 281,012 shares worth $11,373,178 as of recent close. Wall Street’s most bullish Amgen Inc. (NASDAQ:AMGN) analysts are predicting the share price to blow past $224 per share during the next 12 months. The current median share price forecast by them is $204.5, suggesting that the stock could increase 3.41% in that time frame. The average price target of $204.65 calls for a nearly 3.48% increase in the stock price.
Amgen Inc. (AMGN) trading activity significantly improved as the volume at ready counter increased to 3,784,573 shares versus 2,745,110 in average daily trading volume over the past 20 days. So far this year, the volume has averaged about 3,483,417 shares. The share price dropped -2.55% in recent trade and currently has a stock-market value of $127.56B. The shares finished at $197.76, after trading as low as $197.29 earlier in the session. It hit an intraday high Tuesday at $205.74. The stock is now 21.09% above against its bear-market low of $163.31 on April 02, 2018. It has retreated -6.29% since it’s 52-week high of $210.19 reached in September. Now the market price is up 10.67% on the year and up 13.72% YTD.
AMGN’s 50 day simple moving average (SMA 50) price is $197.67 and its 200-day simple moving average (SMA 200) price is $188.71. The company’s stock currently has a total float of 635.9M shares. Its weekly volatility is hovering around 3.42% and felt 2.51% volatility in price over a month. On the upside, the share price will test short term resistance at around $203.24. On a downside, the stock is likely to find some support, which begins at $194.79. The failure to get near-term support could push it to $191.81.
It had seen a new analyst call from Cantor Fitzgerald, which initiated the stock at Neutral on October 01. Analysts at Barclays, maintained the company shares at Equal Weight on April 05 but switched target price from $190 to $180. Brokerage firm Mizuho, looks cautious as they stick to prior recommendation of Buy, in a call on February 12. However, they did change the target price from $192 to $200.
When looking at valuations, Amgen Inc. (AMGN) has a cheap P/E of 16.31x as compared to industry average of 29.45x. Moreover, it trades for 13.62 times the next 12 months of expected earnings. Also, it is trading at rather expensive levels at just over 8.89x price/book and 5.47x price/sales. Compared to others, Amgen Inc. is in a different league with regards to profitability, having net margins of 9.4%. To put some perspective around this, the industry’s average net margin is 5.44%. AMGN’s ROE is 12.6%, which is also considerably worse than the industry’s ROE of 15.85%. It’s also very liquid in the near term, with a current ratio of 3.1. The stock has a debt/capital of 2.4.
Shares of Amgen Inc. (AMGN) have gained 7.3% since the company’s last earnings report. Over the past 12 fiscal quarters, Amgen Inc. (NASDAQ:AMGN) has topped consensus earnings estimates in 11 quarters (91%), missed earnings in 1 quarters (8%), whereas at 0 occasion EPS met analyst expectations. AMGN last reported earnings on October 30, 2018 when it released Sep-18 results that exceeded expectations. The company raked in $3.69 per share, -46.68% change on the same period last year. That was better than consensus for $3.45. Revenue for the recent quarter stood at $5.9 billion, up 2% on last year and above the $5.77 billion predicted by analysts. For this quarter, Wall Street analysts forecast revenue in a range of $5.74 billion to $6.14 billion, which should be compared with $5.85 billion generated last year. EPS is seen in a range of $3.15 to $3.55, against the $3.13 reported a year ago.